Prevention of cytomegalovirus disease in transplant recipients (Q44903852)

7 December 2017

Prevention of cytomegalovirus disease in transplant recipients. (English)

1 reference

7 December 2017

0 references

D J Winston

1

1 reference

PubMed ID

7475816

7 December 2017

language of work or name

English

0 references

publication date

1 November 1995

1 reference

7 December 2017

1 reference

7 December 2017

346

1 reference

7 December 2017

8987

1 reference

7 December 2017

1380-1381

1 reference

Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation

7 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992401-9

7 January 2021

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992401-9

7 January 2021

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992401-9

7 January 2021

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992401-9

7 January 2021

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992401-9

7 January 2021

Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992401-9

7 January 2021

Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992401-9

7 January 2021

A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992401-9

7 January 2021

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992401-9

7 January 2021

Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992401-9

7 January 2021

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2992401-9

7 January 2021

10.1016/S0140-6736(95)92401-9

Identifiers

DOI

1 reference

7 December 2017

1 reference

PubMed ID

7475816